コンテンツへスキップ
Merck

918075

Sigma-Aldrich

NanoFabTx PLA-nano

for synthesis of 100 and 200 nm particles

別名:

For nanoparticle synthesis for drug delivery

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12161503
NACRES:
NA.23

品質水準

アプリケーション

advanced drug delivery

保管温度

2-8°C

詳細

The NanoFabTx Polymer drug formulation kit, PLA, for synthesis of 100 and 200 nm particles is a ready-to-use nanoformulation kit for the synthesis of drug-encapsulating PLA-based nanoparticles. This kit provides properly selected PLA based polymers, stabilizer, and protocols for fabrication of PLA nanoparticles by both nanoprecipitation and microfluidic-based synthesis. The microfluidics protocol uses a NanoFabTx device kits (911593, sold separately), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).Comprehensive protocols for two different particle synthesis methods are included:

  • A nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A microfluidics protocol using commercial platforms or syringe pumps.

アプリケーション

The NanoFabTx Polymer drug formulation kit, PLA, for synthesis of 100 and 200 nm particles enables users to encapsulate a wide variety of therapeutic drug molecules in PLA-based nanoparticles. Drug encapsulated nanoparticles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, antigen delivery, and vaccine delivery. Poly(D,L-lactic acid) (PLA) is a biocompatible and biodegradable polymer that has been approved by the FDA for biomedical and pharmaceutical applications. Because of their robust mechanical properties and slow degradation, PLA based nanoparticles have been widely used as drug delivery systems to achieve controlled drug release for different types of therapeutic molecules. This kit minimizes laboratory setup with optimized protocols and step-by-step instruction for synthesizing drug-encapsulated nanoparticle-based formulations. It is designed to help pharmaceutical researches achieve reproducible synthesis with high loading efficiencies without the need for lengthy trial-and-error optimization.

特徴および利点

  • Ready-to-use nanoformulation kit for PLA nanoparticles
  • Step-by-step protocols developed and tested by our formulation scientists
  • Flexible synthesis tool to create uniform and reproducible nanoparticles
  • Optimized to make nanoparticles 100–200 nm nanoprecipitation or microfluidics with low polydispersity
  • Based on non-toxic, biodegradable polymers

法的情報

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

保管分類コード

11 - Combustible Solids


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

毒物及び劇物取締法

キットコンポーネントの情報を参照してください

PRTR

キットコンポーネントの情報を参照してください

消防法

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を表示すべき危険物及び有害物

キットコンポーネントの情報を参照してください

労働安全衛生法名称等を通知すべき危険物及び有害物

キットコンポーネントの情報を参照してください

カルタヘナ法

キットコンポーネントの情報を参照してください

Jan Code

キットコンポーネントの情報を参照してください


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

S Freiberg et al.
International journal of pharmaceutics, 282(1-2), 1-18 (2004-09-01)
Polymer microspheres can be employed to deliver medication in a rate-controlled and sometimes targeted manner. Medication is released from a microsphere by drug leaching from the polymer or by degradation of the polymer matrix. Since the rate of drug release
C Thomasin et al.
Journal of pharmaceutical sciences, 87(3), 269-275 (1998-04-02)
Phase separation (frequently called coacervation) of poly(lactide) (PLA) and poly(lactide-co-glycolide) (PLGA) is a classical method for drug microencapsulation. Here, attempts have been made to describe this process in the light of thermodynamics. Different PLA/PLGAs were dissolved in either dichloromethane or
Verónica Lassalle et al.
Macromolecular bioscience, 7(6), 767-783 (2007-06-02)
The controlled release of medicaments remains the most convenient way of drug delivery. Therefore, a wide variety of reports can be found in the open literature dealing with drug delivery systems. In particular, the use of nano- and microparticles devices
Byung Kook Lee et al.
Advanced drug delivery reviews, 107, 176-191 (2016-06-06)
Poly(d,l-lactic acid) (PLA) has been widely used for various biomedical applications for its biodegradable, biocompatible, and nontoxic properties. Various methods, such as emulsion, salting out, and precipitation, have been used to make better PLA micro- and nano-particle formulations. They are
Nazila Kamaly et al.
Chemical Society reviews, 41(7), 2971-3010 (2012-03-06)
Polymeric materials have been used in a range of pharmaceutical and biotechnology products for more than 40 years. These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopaedic implants, macroscale and microscale drug delivery

資料

NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.

NanoFabTx™キットは、ナノ粒子・リポソームドラッグデリバリー製剤の迅速かつ十分に制御された合成のために最適化されています。薬物放出挙動が制御された、さまざまな治療薬化合物のカプセル化を行うことができます。

NanoFabTx™DDS製剤プラットフォームは、マイクロ粒子、ナノ粒子またはリポソーム製剤を容易に合成可能なキットです。NanoAssemblr®装置を用いたナノ製剤化事例をご紹介します。

NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)